1. Home
  2. QLGN vs MEGL Comparison

QLGN vs MEGL Comparison

Compare QLGN & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • MEGL
  • Stock Information
  • Founded
  • QLGN 1996
  • MEGL 2016
  • Country
  • QLGN United States
  • MEGL Hong Kong
  • Employees
  • QLGN N/A
  • MEGL N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • MEGL Finance: Consumer Services
  • Sector
  • QLGN Health Care
  • MEGL Finance
  • Exchange
  • QLGN Nasdaq
  • MEGL Nasdaq
  • Market Cap
  • QLGN 7.4M
  • MEGL 6.8M
  • IPO Year
  • QLGN N/A
  • MEGL 2022
  • Fundamental
  • Price
  • QLGN $2.85
  • MEGL $1.54
  • Analyst Decision
  • QLGN
  • MEGL
  • Analyst Count
  • QLGN 0
  • MEGL 0
  • Target Price
  • QLGN N/A
  • MEGL N/A
  • AVG Volume (30 Days)
  • QLGN 3.4M
  • MEGL 52.3K
  • Earning Date
  • QLGN 11-14-2025
  • MEGL 12-11-2025
  • Dividend Yield
  • QLGN N/A
  • MEGL N/A
  • EPS Growth
  • QLGN N/A
  • MEGL N/A
  • EPS
  • QLGN N/A
  • MEGL N/A
  • Revenue
  • QLGN N/A
  • MEGL $1,296,394.00
  • Revenue This Year
  • QLGN N/A
  • MEGL N/A
  • Revenue Next Year
  • QLGN N/A
  • MEGL N/A
  • P/E Ratio
  • QLGN N/A
  • MEGL N/A
  • Revenue Growth
  • QLGN N/A
  • MEGL N/A
  • 52 Week Low
  • QLGN $1.61
  • MEGL $1.02
  • 52 Week High
  • QLGN $8.81
  • MEGL $5.52
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 39.72
  • MEGL 55.37
  • Support Level
  • QLGN $2.66
  • MEGL $1.37
  • Resistance Level
  • QLGN $3.36
  • MEGL $1.46
  • Average True Range (ATR)
  • QLGN 0.55
  • MEGL 0.07
  • MACD
  • QLGN -0.17
  • MEGL -0.00
  • Stochastic Oscillator
  • QLGN 5.74
  • MEGL 62.96

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

About MEGL Magic Empire Global Limited

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

Share on Social Networks: